---
title: Real-World Health Care Resource Use and Costs Among Patients With Chronic Lymphocytic
  Leukemia Treated With Venetoclax-Based and Bruton Tyrosine Kinase Inhibitor-Based
  Regimens in the Second-Line Setting
date: '2024-04-16'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38626366/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20240417180619&v=2.18.0.post9+e462414
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: 'CONCLUSION: Venetoclax was associated with total monthly cost savings
  versus BTKis, illustrating the economic value of time-limited venetoclax-based regimens
  in the 2L ...'
disable_comments: true
---
CONCLUSION: Venetoclax was associated with total monthly cost savings versus BTKis, illustrating the economic value of time-limited venetoclax-based regimens in the 2L ...